NCT04708587View on ClinicalTrials.gov

Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD)

NARecruitingINTERVENTIONAL
Enrollment

900

Participants

Timeline

Start Date

March 23, 2021

Primary Completion Date

March 13, 2027

Study Completion Date

March 13, 2028

Conditions
Chronic Kidney Diseases
Interventions
DRUG

dual anti-platelet therapy at least 6 months

Patients enrolled in dual antiplatelets at least 6 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for at least 6 months after randomization. Clopidogrel or prasugrel should be maintained after 6 months.

DRUG

dual anti-platelet therapy 3months or less

Patient enrolled in the dual antiplatelet therapy less than 3 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for less than 3 months after randomization. After 3 months clopidogrel or prasugrel should be maintained.

Trial Locations (1)

Unknown

RECRUITING

Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER